DALY II USA/ MB-CART2019.1 for DLBCL

Active:	Yes
Cancer Type:	Hematopoietic Malignancies Lymphoma Non-Hodgkin Lymphoma Unknown Primary	NCT ID:	NCT04792489
Trial Phases:	Phase II	Protocol IDs:	M-2018-344 (primary) NCI-2021-08357
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Miltenyi Biomedicine GmbH
NCI Full Details:	http://clinicaltrials.gov/show/NCT04792489

Summary

DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy,
safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients
with relapsed and/or refractory diffuse large B cell lymphoma (DLBCL) after receiving at
least two lines of therapy.

Objectives

A prospective, single arm, open label, multi-center, phase II study of autologous T cells
engineered against both CD19 and CD20 antigens for subjects with relapsed or refractory
DLBCL after receiving at least two lines of therapy. The investigational agent is the
MB-CART2019.1 cells. After successful screening, subjects will undergo leukapheresis to
collect product for manufacturing. In preparation for the fresh product infusion,
subjects will undergo a lymphodepleting regimen with cyclophosphamide and fludarabine, or
bendamustine. Cell infusion will be administered intravenously at a dose of 2.5 x 106
CAR+ cells/kg body weight. The study will start with enrollment of 3 subjects in the
lead-in safety phase, and after safety is evaluated, the study will continue with
enrollment of the remaining subjects. Subjects will be followed for up to 2 years, for
efficacy and safety outcomes as well as health-related quality of life (HRQol).
Additional long-term follow-up will be conducted for participants under a separate
long-term follow-up protocol.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.